High prevalence of HTLV-I infection in Argentinian blood donors: a new HTLV-I-endemic area?
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to L Astarloa.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A serologic study of hepatitis and HIV infections among 99 I.V. drug abusers with hepatitis was conducted between December 1986 and September 1987. The average age of the study subjects was 21 years. Eighty-nine (90%) of the subjects were male, including four whose sexual orientation was homosexual/bisexual. Serologic tests indicated that 87 of the 99 subjects had hepatitis B virus infections, 62 acute and 25 chronic. Nine (10%) of these 87 patients were coinfected with the delta agent. Two subjects had acute cases of hepatitis A, and the 10 remaining subjects had non-A non-B hepatitis. Forty-seven of the study subjects were also found to be infected with HIV-1. The prevalence of the delta marker was surprisingly high, because Argentina has been regarded as nonendemic for the delta virus. Given the trend of increasing I.V. drug abuse in Argentina, these results presage a significant increase in the delta agent's prevalence in the immediate future.
The effects of cytarabine on neurological forms of Argentina Hemorrhagic Fever were evaluated in 125 patients. The mortality was 12.88 per cent compared to 61.40 per cent in untreated patients. (p less than 0.0001). The efficiency of this treatment depends on its early application. No side effect was observed.
During the 23 consecutive annual epidemics of Argentine haemorrhagic fever observed from 1959 to 1983, a group of 4,433 patients were treated at Junin (Argentina) with convalescent's plasma; the overall mortality rate was 3.29%. In 1958, before convalescent's plasma was used, the mortality rate in 448 patients who received the conventional treatment was 42.85%. The difference between the two groups is highly significant and demonstrates the value of convalescent's plasma in the treatment of the disease.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.